NFKB1 and cancer: In summary, miRNA analysis revealed that both pre- or post-treatment of HM with a pharmacologic inhibitor of NF-κB, significantly prevented and suppressed the acidic bile-induced upregulation and downregulation, respectively, of cancer-related miRNA phenotypes [5, 7, 20], as previously shown by the simultaneous topical co-administration of BAY 11-7082 with acidic bile on HM [24].